[Asia Economy Reporter Minji Lee] Tium Bio announced on the 8th that it has submitted a clinical trial application for the Phase 1a study of the hemophilia bypassing agent TU7710 to the Korea Ministry of Food and Drug Safety.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
